These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36854518)

  • 41. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal cell carcinoma: molecularly targeted therapy.
    Cáceres W; Cruz-Chacón A
    P R Health Sci J; 2011 Jun; 30(2):73-7. PubMed ID: 21682150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New agents in renal cell carcinoma.
    Dabney R; Devine R; Sein N; George B
    Target Oncol; 2014 Sep; 9(3):183-93. PubMed ID: 24243495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel targets and therapies for metastatic renal cell carcinoma.
    Feldman DR; Motzer RJ
    Oncology (Williston Park); 2006 Dec; 20(14):1745-53; discussion 1756. PubMed ID: 17263126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
    Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
    BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
    Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
    Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted therapies in the treatment of renal cell carcinoma.
    Pezaro C; Davis ID
    Curr Med Chem; 2008; 15(12):1166-74. PubMed ID: 18473811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in the treatment of metastatic renal cell carcinoma.
    Abe H; Kamai T
    Int J Urol; 2013 Oct; 20(10):944-55. PubMed ID: 23692504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
    Zarrabi K; Wu S
    Curr Oncol Rep; 2018 Apr; 20(5):41. PubMed ID: 29611002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma.
    Ravaud A; Gross-Goupil M
    Cancer Treat Rev; 2012 Dec; 38(8):996-1003. PubMed ID: 22330762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
    Gross-Goupil M; Massard C; Ravaud A
    Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report.
    Daanen RA; Maas RJH; Koornstra RHT; Steenbergen EJ; van Herpen CML; Willemsen AECAB
    J Immunother; 2017; 40(9):345-348. PubMed ID: 28961608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
    Merza H; Bilusic M
    Curr Oncol Rep; 2017 Apr; 19(4):27. PubMed ID: 28303494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Molecular targeted therapy for renal cell carcinoma and other urological cancers].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2010 Oct; 68(10):1871-5. PubMed ID: 20954332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
    Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
    Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
    Choueiri TK
    Curr Clin Pharmacol; 2011 Aug; 6(3):164-8. PubMed ID: 21827394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rational therapy for renal cell carcinoma based on its genetic targets.
    Messer J; Drabick J; Kaag M
    Adv Exp Med Biol; 2013; 779():291-308. PubMed ID: 23288645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK; Rini BI
    Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.